Seoul
South Korea
33
2025-10-23
24
2026-04-21
These are the the leading inventors for applications assigned to Toolgen Incorporated:
Toolgen Incorporated based in Seoul, KR has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:
Compositions for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells
#2 | 2025-05-29 ✅ Patent 12,612,634 granted on 2026-04-28Compositions for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells
#3 | 2025-05-08Compositions for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells
#4 | 2025-05-08Compositions for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells
#5 | 2025-04-17 ✅ Patent 12,612,633 granted on 2026-04-28Compositions for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells
#6 | 2025-02-27 ✅ Patent 12,612,632 granted on 2026-04-28COMPOSITIONS FOR INDUCING MODIFICATIONS OF TARGET ENDOGENOUS NUCLEIC ACID SEQUENCES IN NUCLEUSES OF EUKARYOTIC CELLS
#7 | 2024-07-18 ✅ Patent 12,473,559 granted on 2025-11-18Cas9/RNA Complexes for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells
#8 | 2024-03-28 ✅ Patent 12,509,697 granted on 2025-12-30OLEIC ACID -ENRICHED PLANT BODY HAVING GENETICALLY MODIFIED FAD2 AND PRODUCTION METHOD THEREOF
#9 | 2024-02-15Cas9/RNA Complexes for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells
#10 | 2024-01-25Compositions Comprising Cas9/guide RNA Complexes for Inducing Targeted Disruption of Endogenous Genes in Eukaryotic Cells
#11 | 2023-11-23COMPOSITION FOR CLEAVING A TARGET DNA COMPRISING A GUIDE RNA SPECIFIC FOR THE TARGET DNA AND CAS PROTEIN-ENCODING NUCLEIC ACID OR CAS PROTEIN, AND USE THEREOF
#12 | 2023-11-23COMPOSITION FOR CLEAVING A TARGET DNA COMPRISING A GUIDE RNA SPECIFIC FOR THE TARGET DNA AND CAS PROTEIN-ENCODING NUCLEIC ACID OR CAS PROTEIN, AND USE THEREOF
#13 | 2023-09-21 ✅ Patent 12,163,149 granted on 2024-12-10Artificial genome manipulation for gene expression regulation
#14 | 2023-09-14 ✅ Patent 12,486,521 granted on 2025-12-02PLATFORM FOR EXPRESSING PROTEIN OF INTEREST IN LIVER
#15 | 2023-04-27 ✅ Patent 12,644,107 granted on 2026-06-02TARGET-SPECIFIC CRISPR MUTANT
#16 | 2022-07-21 ✅ Patent 12,286,635 granted on 2025-04-29Oleic acid-enriched plant body having genetically modified FAD2 and production method thereof
#17 | 2022-06-30 ✅ Patent 12,351,838 granted on 2025-07-08TARGET-SPECIFIC CRISPR MUTANT
#18 | 2022-06-23 ✅ Patent 12,642,256 granted on 2026-06-02HEMOPHILIA B RAT MODEL
#19 | 2021-08-19 ✅ Patent 12,241,071 granted on 2025-03-04Composition for editing flavonoid biosynthetic gene by using CRISPR/Cas9 system, and use thereof
#20 | 2021-08-19 ✅ Patent 11,999,952 granted on 2024-06-04Artificially-manipulated neovascularization regulatory system
#21 | 2021-05-20 ✅ Patent 12,275,963 granted on 2025-04-15Artificially manipulated immune cell
#22 | 2021-04-01 ✅ Patent 11,667,934 granted on 2023-06-06Platform for expressing protein of interest in liver
#23 | 2021-02-18COMPOSITION FOR CLEAVING A TARGET DNA COMPRISING A GUIDE RNA SPECIFIC FOR THE TARGET DNA AND CAS PROTEIN-ENCODING NUCLEIC ACID OR CAS PROTEIN, AND USE THEREOF
#24 | 2021-02-18COMPOSITION FOR CLEAVING A TARGET DNA COMPRISING A GUIDE RNA SPECIFIC FOR THE TARGET DNA AND CAS PROTEIN-ENCODING NUCLEIC ACID OR CAS PROTEIN, AND USE THEREOF
#25 | 2020-09-03 ✅ Patent 11,845,951 granted on 2023-12-19Gene manipulation for treatment of retinal dysfunction disorder
#26 | 2020-06-25 ✅ Patent 11,572,574 granted on 2023-02-07Artificial genome manipulation for gene expression regulation
#27 | 2020-05-14 ✅ Patent 11,441,135 granted on 2022-09-13Target-specific CRISPR mutant
#28 | 2020-04-30 ✅ Patent 11,920,151 granted on 2024-03-05Method for identifying DNA base editing by means of cytosine deaminase
#29 | 2019-09-12 ✅ Patent 12,331,086 granted on 2025-06-17ARTIFICIALLY ENGINEERED SC FUNCTION CONTROL SYSTEM
#30 | 2019-06-20 ✅ Patent 12,012,598 granted on 2024-06-18Manipulated immunoregulatory element and immunity altered thereby
#31 | 2017-07-06Method for Sensitive Detection of Target DNA Using Target-Specific Nuclease
#32 | 2017-05-25 ✅ Patent 10,519,454 granted on 2019-12-31Genome editing using CRISPR/CAS system-derived RGEN
#33 | 2015-11-12 ✅ Patent 10,851,380 granted on 2020-12-01Methods for cleaving a target DNA using a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein
Also check out TOOLGEN INCORPORATED's (Seoul, South Korea) applicant profile with 42 patent applications submitted.
124049 ⎘